CTRI/2020/03/024054招募中4 期
A prospective, multi-center, phase IV study to assess the safety, efficacy and immunogenicity of BIOSULIN�® 30:70 (Insulin Injection, Biphasic Isophane 100 IU/ml of M. J. Biopharm Private Limited) in treatment of patients diagnosed with type 2 diabetes mellitus
M J Biopharm Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Patients who are willing to provide written, signed and dated informed consent (IEC/IRB approved) to participate in the study before initiating any study related procedures
- •2. Type II diabetic male or female adult patients, within 18 to 65 years of age(Inclusive)
- •3. Patients who are willing to comply with visit schedule and all aspects of the protocol requirements
- •4. Adult patients with type II diabetes mellitus who require Premix Human Insulin Biphasic 30/70 for the control of hyperglycemia according to the clinical judgment of the physician..
- •5. Patients with glycosylated/glycated hemoglobin (HbA1c) level ââ?°Â¤ 11 % at screening
- •6. Ability to self-inject insulin and perform self-monitoring of blood glucose (SMBG) measurements. Patients whose injection is being administered by caregiver/family member (only in the case wherein the patient has fear to self-inject or does not prefer to self-inject) will be enrolled
排除标准
- •1.History of Type I Diabetes mellitus or secondary diabetes mellitus or diabetes insipidus
- •2. Type 2 diabetic patients with metabolic complication such as diabetic ketoacidosis within 6 months of baseline visit
- •3. Patients who have used any other investigational agent in the past 3 months
- •4. Patients having mental incapacity, unwillingness or language barriers hindering adequate understanding or cooperation
- •5. Patients with history or evidence of hypersensitivity to the active substance (insulin) or to any of the excipients as mentioned in the local prescribing information
- •6. Women who are pregnant or nursing mothers. Women of childbearing potential not willing to use acceptable method of contraception
- •7. Any disorder which in the opinion of the treating physician might jeopardize subjectââ?¬•s safety or compliance with the protocol
- •8. Patient who has received/receiving insulin of animal origin
- •9. Patient with history or evidence of recurrent severe hypoglycemia within 6 months at baseline visit
- •10. Patients with use of insulin pump within 6 months at baseline visit
- •11. Patientââ?¬•s having the any of the following laboratory results at screening
- •a. BUN > 30 mg/dL
- •b. ALT/AST levels ââ?°Â¥ 2.5 X ULN of the normal laboratory range
- •c. Serum creatinine level >2.0 mg/dL
- •12. Patients with known history of positive serology for hepatitis B virus (HBV) or hepatitis C (HCV) or human immunodeficiency virus (HIV) infections
- •13. Patients receiving glucagon-like peptide 1 mimetics (GLP-1)
- •14. Patients receiving treatment with thiazolidinedione (TZD) within the last 3 months at baseline visit
- •15. Patients with body mass index (BMI) <18 kg/mÃ?² and ââ?°Â¥40 kg/mÃ?² at screening
- •16. Patients who have undergone pancreatectomy or pancreas islet transplant or renal transplant
- •17. Patients receiving or have received within the last year any immunomodulation medications that would possibly modify antibody generation either at the enrollment or during the course of the study
- •18. Patients who have received/receiving ( >14 consecutive days) glucocorticoids within 4 weeks prior to baseline visit
- •19. Patients with history or evidence of diabetic complications (diabetic retinopathy, diabetic neuropathy, or diabetic nephropathy), other complications related to T2DM other than those mentioned, or cardiac disorders, etc. which in the opinion of the investigator signifies patientsââ?¬• ineligibility for the trial
- •20. Patients with alcohol or drug abuse or any other medical or surgical condition, including lifestyle (e.g. shift workers, irregularity with meal times, etc.) that in the opinion of investigator can interfere with the study protocol or affect patientââ?¬•s safety in the study
研究者
相似试验
已完成
4 期
Phase -IV study to check the safety of fixed dose combination of dapagliflozin and saxagliptin in Indian Type 2 Diabetes Mellitus patientsCTRI/2021/02/031471AstraZeneca Pharma India Ltd196
招募中
4 期
This research study will be conducted to understand the side effects and effectiveness of the already marketed medicine named as SomatoRel™ (recombinant human growth hormone) in growth hormone deficient children (child is significantly shorter than children his or her age)CTRI/2020/07/026292Reliance Life Sciences Pvt Ltd RLS
已完成
4 期
The purpose of this research study is to evaluate the safety and effectiveness profile of the medicine named as EtanerRelTM in patients with different type of arthritis (joint pain)CTRI/2021/06/034073Reliance Life Sciences Pvt Ltd230
进行中（未招募）
4 期
The post marketing clinical research on drug Tenecteplase in patients with ST segment elevation myocardial infarction or left bundle branch blockCTRI/2020/07/026356Reliance Life Sciences Pvt Ltd
进行中（未招募）
1 期
A phase IV prospective, multicentre, randomized, open-label trial to assess the efficacy and safety of GONAL f® at a dose based on subject baseline characteristics determined according to the CONSORT calculator compared with a standard dose of GONAL f® 150 IU per day for ovarian stimulation in women undergoing assisted reproductive technology (ART) - CONSORT RCT in ARTEUCTR2008-001259-22-FRMerck Serono International S.A.